Drug

Zhongsheng Pharma's RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING‑2 Trial – Biweekly GLP‑1/GIP Dual Agonist Outperforms Tirzepatide Response Rates on Key Thresholds
Clinical trial resultsHot targets

Zhongsheng Pharma’s RAY1225 Achieves 22.2% Weight Loss in Phase III REBUILDING‑2 Trial – Biweekly GLP‑1/GIP Dual Agonist Outperforms Tirzepatide Response Rates on Key Thresholds

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive topline results from its Phase III REBUILDING‑2 clinical trial evaluating RAY1225 Injection (Bilpatide Injection), a first‑in‑class dual GLP‑1/GIP receptor agonist with…

Lifotronic Technology's H100Plus HbA1c Testing System Receives FDA 510(k) Clearance – Chinese IVD Company Gains U.S. Market Access for Diabetes Diagnostics

Lifotronic Technology’s H100Plus HbA1c Testing System Receives FDA 510(k) Clearance – Chinese IVD Company Gains U.S. Market Access for Diabetes Diagnostics

Hinova Pharmaceuticals' HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs

Hinova Pharmaceuticals’ HP515 Phase IIa MASH Data Accepted as AASLD 2026 Late‑Breaking Abstract – THR‑β Agonist Achieves >50% Liver Fat Reduction With No SAEs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationJecho Biopharmaceuticals

Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors – Novel Bispecific Fc Fusion Protein Targets “Cold Tumors”

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
NovartisNYSE: NVS

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

BeBetter Medicine TechnologyClinical trial approval / initiation

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Clinical trial resultsHinova Pharmaceuticals

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Show More